Data as of Mar 07
| +0.51 / +4.51%|
Conatus Pharmaceuticals, Inc. is a biotechnology company. It focuses on the development and commercialization of novel medicines to treat liver disease. The company is engaged in developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Emricasan is a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. Conatus Pharmaceuticals was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in San Diego, CA.
|Steven J. Mento||President, Chief Executive Officer & Director|
|Charles J. Cashion||Chief Financial Officer, Secretary & SVP|
|Alfred P. Spada||CSO & Senior Vice President-Research & Development|
|Gary Craig Burgess||Chief Medical Officer & SVP-Clinical Research|
|Mark F. Morris||Head-Biostatistics|